Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

doi:10.1016/S0169-5002(08)70099-0

Back to search

Article

Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.

Lung cancer (Amsterdam, Netherlands) - 1 Jun 2008

Jänne Pasi A

Abstract excerpt

For patients with advanced non-small cell lung cancer (NSCLC), the introduction of the epi- dermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, into clinical practice was promising. Treatment with either of these agents is associated with an objective...

Topics

Alleles
Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Drug Resistance, Neoplasm
ErbB Receptors
Erlotinib Hydrochloride
Gefitinib
Gene Expression Regulation, Neoplastic
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Proto-Oncogene Mas
Quinazolines

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.